NBbiolab provides a serials of VHH, which product by recombination. From premade to immunized phage display library, our proprietary VHH platform allows rapid generation and large-scale production of high affinity novel, high specificity VHH.

VHH are single-domain antibodies derived from the variable regions of heavy chain of Camelidae immunoglobulin, also called SdAbs. The VHH technology was originally developed following the discovery that camelidae, unlike mouse, rat or rabbit, possess fully functional antibodies that lack light chains. Therefore, the size of VHH is extremely small compared to other forms of antibody fragment, which significantly increase the permeability of VHH.Thus VHH is considered of great value for research, diagnostics and therapeutics.

Benefits of VHH antibodies

Framework: The 12-15 kDa antigen-binding VHH domain acts as a framework for recombinant antibody production. VHH antibod-ies can be designed in a variety of structural formats.Targeting: The small size and long CDR3 loop of the VHH antibodies allows better access to cryptic epitopes compared to conventional antibodies.

Stability: VHH antibodies have good solubility and are stable to heat, proteases and pH extremes.

Production: VHH antibodies are easy to clone and modify. They can be produced recombinantly at high levels in bacterial, yeast, and mammalian expression systems. Their design can include tags for purification, or functional groups to enable the addition of drugs or fluorescent probes.